Chemotherapy in hormone-refractory prostate cancer.
Research in the past 3 decades has resulted in new approaches to treat patients with hormone-refractory prostate cancer. Employing the new treatment options, we are now able to prolong survival in these patients. At present, docetaxel given on a 3-week schedule is the standard of care for patients with hormone-refractory prostate cancer. Several new treatments are under investigation in phase III trials and will further improve the treatment options for these patients within the next years.
Department of Urology, Caritas-Krankenhaus, Bad Mergentheim , Germany.
Johannes Maria
JM
Wolff
D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
D000726:Androgen Antagonists; D000970:Antineoplastic Agents